Coating Janus Nanoparticles with Immunoregulatory Protein Embedded Membrane for Enhanced Anti‐Inflammatory and Sonodynamic Therapy of Psoriasis
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503942 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Chunpeng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, and Department of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin, 15…. Hauptthemen laut MEDLINE: Psoriasis, Nanoparticles, Ultrasonic Therapy, Anti-Inflammatory Agents. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Heilongjiang Postdoctoral Science Foundation.
Abstract (Originalsprache)
The interplay between keratinocyte (KC) hyperproliferation and T cell activation underpins psoriasis pathogenesis, posing significant challenges for effective treatment. Here, cell membrane‐coated nanoparticles (CNPs) are designed to simultaneously inhibit T cell activation and KC hyperproliferation for optimized psoriasis therapy. A customized cell membrane is genetically engineered to overexpress the immunoregulatory V‐domain immunoglobulin suppressor of T cell activation (VISTA) protein to enable potent T‐cell inhibition. The encapsulated core is designed as Janus nanoparticles (mSiO 2 &rPMO) for co‐delivery of hydrophilic 5‐aminolevulinic acid (5‐ALA) and hydrophobic tazarotene, facilitating synergistic sonodynamic therapy (SDT) and anti‐inflammatory effects. Mechanistically, under ultrasound stimulation, accumulated protoporphyrin IX (PpIX) derived from 5‐ALA metabolism generates reactive oxygen species (ROS) that inhibit epidermal proliferation, while tazarotene activates retinoic acid receptor gamma (RARγ) to exert anti‐inflammatory effects. Concurrently, the VISTA‐overexpressed membrane enhances anti‐inflammatory responses, further amplifying the anti‐psoriatic effect. CNP efficacy in a psoriatic mouse model is validated, demonstrating mitigated lesion severity, suppressed epidermal hyperplasia, and reduced inflammatory cytokine levels in skin lesions. Notably, CNPs outperformed non‐membrane counterparts in both cellular and animal models, highlighting the anti‐psoriatic amplification conferred by the engineered membrane. Overall, this research presents a novel therapeutic strategy for psoriasis management using engineered membrane‐coated mesoporous Janus nanoparticles to target keratinocyte proliferation and T cell activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, and Department of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin, 150081, China.
- Research Center for Pharmacoinformatic, College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
ORCID-Profile: Manjie Zhang
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Heilongjiang Postdoctoral Science Foundation
- Natural Science Foundation of Heilongjiang Province
- Harbin Medical University high-level introduction of talent research start-up fund
Zitieren
APA
Zhang, C., Chi, H., Pang, X., Liu, J., Sun, B., & Zhang, M. (2026). Coating Janus Nanoparticles with Immunoregulatory Protein Embedded Membrane for Enhanced Anti‐Inflammatory and Sonodynamic Therapy of Psoriasis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503942
Vancouver
Zhang C, Chi H, Pang X, Liu J, Sun B, Zhang M. Coating Janus Nanoparticles with Immunoregulatory Protein Embedded Membrane for Enhanced Anti‐Inflammatory and Sonodynamic Therapy of Psoriasis. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503942
BibTeX
@article{Zhang2026,
author = {Zhang, Chunpeng and Chi, Hang and Pang, Xinyu and Liu, Jiaxin and Sun, Bin and Zhang, Manjie},
title = {Coating Janus Nanoparticles with Immunoregulatory Protein Embedded Membrane for Enhanced Anti‐Inflammatory and Sonodynamic Therapy of Psoriasis},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503942}
}
EUVIMED